Acumen reported new research findings in one oral and two poster presentations at the AD/PD conference taking place in Copenhagen and online. In a mouse study, the company evaluated bispecific versions of sabirnetug that target the transferrin receptor, with plasma and brain pharmacokinetics measured after a 2 mg/kg IV injection. In exploratory biomarker work from the Phase 1 INTERCEPT-AD study, Acumen used the NULISAseq CNS Disease Panel to measure 127 proteins and reported treatment-associated changes including the pTau217/Aβ42 ratio. In antibody discovery research, Acumen identified three anti-amyloid beta oligomer monoclonal antibodies, including ACU234 with about 21,000-fold higher affinity for oligomers than monomeric Aβ.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603170800PRIMZONEFULLFEED9672069) on March 17, 2026, and is solely responsible for the information contained therein.